Novo Holdings and Associates partner with Biocomposites to drive next chapter of its growth | News & Insights
Summary
Additional investment and resources will accelerate Biocomposites international expansion and innovation in products for use in infection managementHELLERUP, Denmark, LONDON and KEELE, England Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo Holdings to make an investment in Biocomposites ("the Company"), an international medical devices company that engineers, manufactures and markets leading products for use in infection management in bone and soft tissue. With the new investment from Novo Holdings and the ongoing support of TA, Biocomposites aims to build on this momentum, deepening its global footprint and further advancing its pipeline of innovative products to deliver life-changing solutions at scale. With our deep expertise in life sciences and extensive global network, we look forward to supporting Biocomposites in expanding its international footprint, driving innovation, and advancing its ability to deliver highly effective and targeted infection management solutions that improve patient outcomes worldwide. With the combined expertise and support of these two leading global healthcare investors, we believe we are well positioned to deliver on our commitment to bring ever more innovative products for use in infection management to more people worldwide - transforming patient outcomes and improving their lives. "The Company has consistently demonstrated its ability to scale internationally while building out a diversified product portfolio that aligns with growing market demand and meets evolving patient needs.